|
Mr. Brunk is a Venture Partner at MDS Capital where he established the firm's Boston office. He has 16 years of operational and investing experience with life science companies. Before joining MDS Capital, he was an entrepreneur in the life science sector, founding and serving as an executive and director at three venture capital-funded companies in the bioinformatics and health care IT sectors. Earlier, he was an engagement manager in the health care practice of The Boston Consulting Group where he advised pharmaceutical and biotechnology firms on strategic issues involving portfolio management, product licensing, research and clinical development productivity, corporate acquisitions and post-merger integration. Prior to joining BCG, Mr. Brunk was a member of the investment banking group of Credit Suisse First Boston where his clients included biotechnology and health care service companies.
Mr. Brunk holds a B.A. with honors from the University of Virginia, where he studied biology and economics, and an M.B.A. from Stanford University Graduate School of Business. He currently serves or has served on the boards of AdipoGenix, Inc., LaConner Technologies, Targanta Therapeutics Inc., and is an observer on the board of Pharmasset, Inc | 